SCHEMBL1083779

SCHEMBL1083779

Clc1ccccc1-c1nc(NCc2ccccc2)c2ccccc2n1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 8/20 0.80
CYP3A4 P08684 8/20 0.80
CYP2D6 P10635 7/20 0.80
CYP2C19 P33261 6/20 0.80
MAPK1 P28482 5/20 0.80
TSHR P16473 5/20 0.80
CLK4 Q9HAZ1 4/20 0.80
USP2 O75604 4/20 0.80
ALDH1A1 P00352 4/20 0.80
MEN1 O00255 4/20 0.71
KMT2A Q03164 4/20 0.71
USP1 O94782 3/20 0.71
WDR48 Q8TAF3 3/20 0.71
POLB P06746 1/20 0.71
MAPT P10636 1/20 0.71
RXFP1 Q9HBX9 1/20 0.71
LMNA P02545 3/20 0.70
CYP2C9 P11712 2/20 0.70
APEX1 P27695 1/20 0.70
CASP7 P55210 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4091164 0.87 PDE5A (0.65) CYP1A2CYP3A4CYP2D6CYP2C19MAPK1
SCHEMBL1083874 0.83 MAPK1 (1.00) CYP1A2CYP3A4CYP2D6CYP2C19MAPK1
SCHEMBL1084041 0.83 KMT2A (1.00) CYP1A2CYP3A4CYP2D6CYP2C19MAPK1
SCHEMBL1083949 0.83 KMT2A (0.71) CYP1A2CYP3A4CYP2D6CYP2C19MAPK1
SCHEMBL28805460 0.83 CYP1A2 (0.80) CYP1A2CYP3A4CYP2D6CYP2C19MAPK1
SCHEMBL13300259 0.82 CYP1A2 (0.71) CYP1A2CYP3A4CYP2D6CYP2C19MAPK1
SCHEMBL1083763 0.81 PDE5A (1.00) CYP1A2CYP3A4CYP2D6CYP2C19MAPK1
SCHEMBL2583256 0.81 PDE5A (0.90) CYP1A2CYP3A4CYP2D6CYP2C19MAPK1
SCHEMBL13984093 0.80 CYP1A2 (0.72) CYP1A2CYP3A4CYP2D6CYP2C19MAPK1
SCHEMBL12176096 0.80 MEN1 (0.71) CYP1A2CYP3A4CYP2D6CYP2C19MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103068393-A Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase CLEAVE BIOSCIENCES INC CLEAVE 2013-04-24 CN disclosed
EP-2566480-A2 METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE California Institute of Technology (US) 2013-03-13 EP disclosed
US-8343980-B2 Quinazoles useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-01 US disclosed
US-8343980-B2 Quinazoles useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-01 US disclosed
US-8153642-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-10 US disclosed
US-8153642-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-04-10 US disclosed
WO-2011140527-A2 METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE CALIFORNIA INSTITUTE OF TECHNOLOGY AND THE UNIVERSITY OF KANSAS (US) 2011-11-10 WO disclosed
WO-2011140527-A2 METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE CALIFORNIA INSTITUTE OF TECHNOLOGY AND THE UNIVERSITY OF KANSAS (US) 2011-11-10 WO disclosed
US-7713983-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-11 US disclosed
US-7713983-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-11 US disclosed
US-7678802-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-03-16 US disclosed
US-7678802-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-03-16 US disclosed